About Amgen

Our Mission:
To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES
We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

TRANSFORMATIVE RESEARCH
Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen’s discovery research efforts—and a major contributor to the development of Amgen’s deep and broad pipeline of potential new medicines. Amgen’s “biology first” approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS BIOMANUFACTURING
The treatment of millions of seriously patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

PRODUCTS
Aimovig® (erenumab-aooe)
AMG EVITA™ (adalimumab)
Aranesp® (darbepoetin alfa)
AVSOLA™ (infliximab-axxq)
BLINCYTO® (bilpatumomab)
Corlanor® (ivabradine)
Enbrel® (etanercept)
EPOGEN® (epoetin alfa)
EVERIITY® (romosozumab-aqpp)
IMLYCI® (taliromogene laherparepvec)
KANJINTI™ (trastuzumab-anns)
KYPROLIS® (carfilzomib)
MAVI® (bevacizumab-awwb)
Neulasta® (pegfilgrastim)
NEUPOGEN® (filgrastim)
Nplate® (romiplostim)
Otezla® (apremilast)
Parsabiv® (etelcalcetide)
Prolia® (denosumab)
Repatha® (evolocumab)
Sensipar®/Mimpara® (cinacalcet)
Vectibix® (panitumumab)
XGEVA® (denosumab)

Aimovig® is developed in collaboration with Novartis. For information about our pipeline and therapies, visit www.amgen.com.
OUR HERITAGE
Building on advances in recombinant DNA and molecular biology, Amgen is counted among the early pioneers of biotechnology. Since 1980, Amgen scientists have been at work developing novel therapies for patients with serious illnesses. Our scientists have characterized key biologic processes that have led to the development of innovative, first-in-class therapies. We have helped shape the scientific world’s understanding of certain disease processes, and we have engineered new types of therapeutic platforms. As a company, we could not have accomplished what we have were it not for our deep commitment to building a culture that embraces science and innovation—a culture that continues to shape who we are today.

THE AMGEN FOUNDATION
The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated nearly $300 million in grants to local, regional and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience and Amgen Teach. For more information, visit www.AmgenInspires.com.

REACHING PATIENTS WORLDWIDE
Amgen medicines help patients worldwide with facilities or subsidiaries in the following locations:

In the United States
California (South San Francisco, Thousand Oaks)
Florida (Tampa)
Kentucky (Louisville)
Massachusetts (Cambridge, Woburn)
Puerto Rico (Juncos)
Rhode Island (West Greenwich)
Washington, D.C.

Outside the United States
Algeria Argentina Australia Austria Belgium Brazil Bulgaria Canada Colombia Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hong Kong Hungary Iceland India Ireland Israel Italy Japan Jordan Korea Latvia Lebanon Lithuania Luxembourg Mexico Morocco Netherlands New Zealand Norway Poland Portugal Romania Russia Saudi Arabia Singapore Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Turkey United Arab Emirates United Kingdom

Investor Information
This fact sheet is a summary of more detailed disclosure that can be found in Amgen’s filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen’s most recent Forms 10-K, 10-Q, and 8-K and on http://investors.amgen.com. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

SENIOR MANAGEMENT
Robert A. Bradway
Chairman and Chief Executive Officer
Victoria H. Blatter
SVP, U.S. Government Affairs
Judy Gawlik Brown
SVP, Corporate Affairs
Tia Bush
SVP, Quality
Raymond Deshaies
SVP, Global Research
Steven K. Galson
SVP, Research and Development
Murdo Gordon
EVP, Global Commercial Operations
Jonathan Graham
EVP, General Counsel and Secretary
Peter Griffith
EVP and Chief Financial Officer
Nancy Grygieł
SVP, Worldwide Compliance & Business Ethics and Chief Compliance Officer
Lori Johnston
EVP, Human Resources
Robert Lenz
SVP, Global Development
Elliott M. Levy
SVP, Research and Development Strategy and Operations
Gilles Marrache
SVP, Regional General Manager
Jerry Murry
SVP, Process Development
Arleen Paulino
SVP, Manufacturing
David A. Piacquadio
SVP, Business Development
Annalisa Pizzarelli
SVP, Results Delivery Office
David M. Reese
EVP, Research and Development
Esteban Santos
EVP, Operations
Darryl Sleep
SVP, Global Medical and Chief Medical Officer
Susan Sweeney
SVP, Global Product Strategy and Commercial Innovation
Mark Taisey
SVP, Global Regulatory Affairs
Ian Thompson
SVP, Regional General Manager
Michael Zahigian
SVP, Chief Information Officer